
Eiger BioPharmaceuticals (EIGR) Stock Forecast & Price Target
Eiger BioPharmaceuticals (EIGR) Analyst Ratings
Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%
Eiger BioPharmaceuticals (EIGR) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.
This aggregate rating is based on analysts' research of Eiger BioPharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
This aggregate rating is based on analysts' research of Eiger BioPharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Eiger BioPharmaceuticals (EIGR) Analyst Forecast & Price Prediction
Get the latest Eiger BioPharmaceuticals (EIGR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Start investing in Eiger BioPharmaceuticals (EIGR)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Eiger BioPharmaceuticals (EIGR) Forecast
Analysts have given Eiger BioPharmaceuticals (EIGR) a Strong Buy based on their latest research and market trends.
According to 9 analysts, Eiger BioPharmaceuticals (EIGR) has a Strong Buy consensus rating as of Jul 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.
Wall Street analysts have set a price target of $27.56, reflecting a 0.00% increase from the current stock price.
Financial analysts have set a price target of $27.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.